Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 17/20 | 0.50 |
| ▸ | DRD3 | P35462 | 16/20 | 0.50 |
| ▸ | DRD4 | P21917 | 12/20 | 0.50 |
| ▸ | HTR2A | P28223 | 8/20 | 0.50 |
| ▸ | DRD1 | P21728 | 7/20 | 0.50 |
| ▸ | HTR1A | P08908 | 4/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4907680 | 0.99 | DRD2 (0.49) | DRD2DRD3DRD4HTR2ADRD1 | |
| SCHEMBL4907687 | 0.88 | DRD2 (0.61) | DRD2DRD3DRD4HTR2ADRD1 | |
| Trifluoroacetic Acid SCHEMBL4917251 | 0.88 | DRD2 (0.55) | DRD2DRD3DRD4HTR2ADRD1 | |
| SCHEMBL4907425 | 0.87 | DRD2 (0.60) | DRD2DRD3DRD4HTR2ADRD1 | |
| Trifluoroacetic Acid SCHEMBL4906668 | 0.87 | DRD2 (0.55) | DRD2DRD3DRD4HTR2ADRD1 | |
| SCHEMBL4918268 | 0.87 | DRD2 (0.57) | DRD2DRD3DRD4HTR2ADRD1 | |
| SCHEMBL4913554 | 0.86 | DRD2 (0.51) | DRD2DRD3DRD4HTR2ADRD1 | |
| SCHEMBL4907488 | 0.86 | DRD2 (0.57) | DRD2DRD3DRD4HTR2ADRD1 | |
| SCHEMBL4916875 | 0.85 | DRD2 (0.50) | DRD2DRD3DRD4HTR2ADRD1 | |
| SCHEMBL4910245 | 0.85 | DRD2 (0.60) | DRD2DRD3DRD4HTR2ADRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778685-B1 | INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF | SANOL ARZNEI SCHWARZ GMBH (DE) | 2008-03-26 | — | — | EP | claimed |
| US-20080051409-A1 | Indolizine Carboxamides and Aza and Diaza Derivatives Thereof | SCHWARZ PHARMA AG (DE) | 2008-02-28 | — | — | US | claimed |
| EP-1778685-A1 | INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF | SCHWARZ PHARMA AG (DE) | 2007-05-02 | — | — | EP | claimed |
| WO-2006015737-A1 | INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF | SCHWARZ PHARMA AG (DE) | 2006-02-16 | — | — | WO | claimed |
| EP-1778685-B1 | INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF | SANOL ARZNEI SCHWARZ GMBH (DE) | 2008-03-26 | — | — | EP | disclosed |
| US-20080051409-A1 | Indolizine Carboxamides and Aza and Diaza Derivatives Thereof | SCHWARZ PHARMA AG (DE) | 2008-02-28 | — | — | US | disclosed |
| EP-1778685-A1 | INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF | SCHWARZ PHARMA AG (DE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006015737-A1 | INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF | SCHWARZ PHARMA AG (DE) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051409-A1 | Indolizine Carboxamides and Aza and Diaza Derivatives Thereof | GRIN2A, GRIN2C, GRIN1 | DRD2 248/4885DRD3 474/4885DRD4 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.